.png){kind=icon}
.png){kind=icon}
Return
Randomized trial of two fractionation schedules of myeloablative busulfan with fludarabine and cladribine in AML or MDS
.png){kind=icon}
PRE
AI
U
K
R
J
B
A
A
G
Q
C
J
P
I
D
R
Y
B
A
M
J
DOI：10.1016/j.jtct.2026.06.014.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Phase two trial examining safety and efficacy of extended busulfan fractionation. • Recipients of longer busulfan fractionation had fewer severe toxicities. • Extending busulfan fractionation did not adversely affect relapse or NRM rates.
Journal
IF:
4.4
Papers:
2.1K
Citations:
4.4K
Organization
No organization information available
Cited Papers